Literature DB >> 16546474

Discordance between insulin resistance and metabolic syndrome: features and associated cardiovascular risk in adults with normal glucose regulation.

Altan Onat1, Gülay Hergenç, Serdar Türkmen, Mehmet Yazici, Ibrahim Sari, Günay Can.   

Abstract

The aims of this study were to investigate the extent of concordance between metabolic syndrome (MS) and insulin resistance (IR), the features of discordance, and the magnitude of their independent association with cardiovascular disease (CVD) risk. After exclusion of individuals with diabetes and impaired fasting glucose, the population sample of 1534 men and women, representative of Turkish adults (mean age, 52.2 years), were evaluated cross-sectionally and at a mean 2 years' follow-up. Metabolic syndrome was identified by criteria of the Adult Treatment Panel III, except for male waist circumference (>94 cm). Insulin resistance was defined by the upper quartile in the sample (>2.245) of the homeostatic model assessment (HOMA) index. Clinical fatal and nonfatal CVD existed or developed in 165 subjects. Waist circumference proved to be by far the strongest significant determinant of HOMA in both sexes, followed by triglycerides. The cohort was categorized into 4 by the presence or absence of MS and IR. Each of the latter represented 34% and 25%, but together constituted 45% of the sample, thus disclosing concordance in a third of the conditions combined. The nonconcordant IR/NoMS group was less common than the MS/NoIR group and was distinct from the latter in having significantly lower waist girth, blood pressure, apolipoprotein B and triglyceride levels, and higher high-density lipoprotein cholesterol, glucose, and insulin levels and physical activity in both sexes. When adjusted for 5 important risk factors, although the excess risk in men with MS failed to attain significance, men with IR were associated with a significant 1.9-fold CVD risk. The IR/NoMS group had a 2.2-fold (95% confidence interval, 0.97-5.11) CVD likelihood compared with the large insulin-sensitive group, after adjustment for age, sex, log C-reactive protein, low-density lipoprotein cholesterol, smoking status, physical activity, and the 2 groups of MS with or without IR. Overlapping between MS and IR is limited in either sex, and MS/NoIR is more common than IR/NoMS. Overall, IR is more significantly associated with CVD risk than MS in men and in both sexes after adjustment for important confounders. Insulin resistance without MS tends to implicate in middle-aged and elderly Turkish men roughly a 2-fold CVD risk, corresponding to 50% excess risk per 1 SD in HOMA index, independent of MS and important covariates.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16546474     DOI: 10.1016/j.metabol.2005.10.005

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  10 in total

1.  Homeostasis model assessment of insulin resistance and the risk of cardiovascular events in middle-aged non-diabetic Japanese men.

Authors:  K Nakamura; M Sakurai; K Miura; Y Morikawa; M Ishizaki; K Yoshita; T Kido; Y Naruse; H Nakagawa
Journal:  Diabetologia       Date:  2010-05-26       Impact factor: 10.122

Review 2.  Management of obesity in the elderly: too much and too late?

Authors:  R L Kennedy; U Malabu; M Kazi; V Shahsidhar
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

3.  Obstructive sleep apnea syndrome is associated with metabolic syndrome rather than insulin resistance.

Authors:  Altan Onat; Gülay Hergenç; Hüseyin Uyarel; Mehmet Yazici; Mustafa Tuncer; Yüksel Doğan; Günay Can; Kurt Rasche
Journal:  Sleep Breath       Date:  2007-03       Impact factor: 2.816

Review 4.  Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?

Authors:  Kyle J Burghardt; Vicki L Ellingrod
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

5.  Correlation between metabolic syndrome and knee osteoarthritis: data from the Korean National Health and Nutrition Examination Survey (KNHANES).

Authors:  Chang Dong Han; Ik Hwan Yang; Woo Suk Lee; Yoo Jung Park; Kwan Kyu Park
Journal:  BMC Public Health       Date:  2013-06-22       Impact factor: 3.295

6.  Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study.

Authors:  Francesco Ursini; Emilio Russo; Marta Letizia Hribal; Daniele Mauro; Francesca Savarino; Caterina Bruno; Cesare Tripolino; Mariangela Rubino; Saverio Naty; Rosa Daniela Grembiale
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

7.  Sex Differences in the Association Between Insulin Resistance and Incident Coronary Heart Disease and Stroke Among Blacks Without Diabetes Mellitus: The Jackson Heart Study.

Authors:  Valery S Effoe; Lynne E Wagenknecht; Justin B Echouffo Tcheugui; Haiying Chen; Joshua J Joseph; Rita R Kalyani; Ronny A Bell; Wen-Chih H Wu; Ramon Casanova; Alain G Bertoni
Journal:  J Am Heart Assoc       Date:  2017-02-02       Impact factor: 5.501

8.  Waist circumference and insulin resistance: a cross-sectional study of Japanese men.

Authors:  Shinji Tabata; Shinichiro Yoshimitsu; Tadamichi Hamachi; Hiroshi Abe; Keizo Ohnaka; Suminori Kono
Journal:  BMC Endocr Disord       Date:  2009-01-12       Impact factor: 2.763

9.  The role of mediastinal adipose tissue 11β-hydroxysteroid d ehydrogenase type 1 and glucocorticoid expression in the development of coronary atherosclerosis in obese patients with ischemic heart disease.

Authors:  Fatmahan Atalar; Selcuk Gormez; Baris Caynak; Gokce Akan; Gamze Tanriverdi; Sema Bilgic-Gazioglu; Demet Gunay; Cihan Duran; Belhhan Akpinar; Ugur Ozbek; Ahmet Sevim Buyukdevrim; Zeliha Yazici
Journal:  Cardiovasc Diabetol       Date:  2012-09-25       Impact factor: 9.951

Review 10.  Therapeutic Options Targeting Oxidative Stress, Mitochondrial Dysfunction and Inflammation to Hinder the Progression of Vascular Complications of Diabetes.

Authors:  João S Teodoro; Sara Nunes; Anabela P Rolo; Flávio Reis; Carlos M Palmeira
Journal:  Front Physiol       Date:  2019-01-17       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.